MA47508A - Protéines de liaison à cd33, nkg2d et cd16 - Google Patents
Protéines de liaison à cd33, nkg2d et cd16Info
- Publication number
- MA47508A MA47508A MA047508A MA47508A MA47508A MA 47508 A MA47508 A MA 47508A MA 047508 A MA047508 A MA 047508A MA 47508 A MA47508 A MA 47508A MA 47508 A MA47508 A MA 47508A
- Authority
- MA
- Morocco
- Prior art keywords
- nkg2d
- binding proteins
- proteins
- binding
- Prior art date
Links
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 title 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 title 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461145P | 2017-02-20 | 2017-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47508A true MA47508A (fr) | 2021-03-17 |
Family
ID=63169992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047508A MA47508A (fr) | 2017-02-20 | 2018-02-20 | Protéines de liaison à cd33, nkg2d et cd16 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210130471A1 (enExample) |
| EP (1) | EP3583131A4 (enExample) |
| JP (3) | JP2020510646A (enExample) |
| KR (1) | KR20190120775A (enExample) |
| CN (1) | CN110573530A (enExample) |
| AU (1) | AU2018220734B2 (enExample) |
| BR (1) | BR112019017277A2 (enExample) |
| CA (1) | CA3054078A1 (enExample) |
| IL (1) | IL268790A (enExample) |
| MA (1) | MA47508A (enExample) |
| SG (1) | SG11201907638QA (enExample) |
| WO (1) | WO2018152516A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3877414A1 (en) * | 2018-11-07 | 2021-09-15 | CRISPR Therapeutics AG | Anti-cd33 immune cell cancer therapy |
| CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| CN116261567A (zh) * | 2020-07-03 | 2023-06-13 | 纽约市哥伦比亚大学理事会 | 多功能性正交蛋白嵌合体 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
| CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025245271A1 (en) * | 2024-05-21 | 2025-11-27 | Dragonfly Therapeutics, Inc. | Anti-nkg2d antibodies and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1423700A (zh) * | 2000-03-24 | 2003-06-11 | 麦克美特股份公司 | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| PL2222706T5 (pl) * | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| US10174117B2 (en) * | 2013-06-11 | 2019-01-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| EP3152235B1 (en) * | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| AU2015301460B2 (en) * | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| DK3029137T3 (en) * | 2014-12-06 | 2019-04-08 | Gemoab Monoclonals Gmbh | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF |
| WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| JP2018517415A (ja) * | 2015-06-10 | 2018-07-05 | ナントクエスト インコーポレイテッド | がんを処置するための改変ｎｋ−９２細胞 |
| AU2016284866B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP2020506971A (ja) * | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
-
2018
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en not_active Abandoned
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Ceased
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/en not_active Ceased
- 2018-02-20 BR BR112019017277-7A patent/BR112019017277A2/pt unknown
- 2018-02-20 CA CA3054078A patent/CA3054078A1/en active Pending
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 AU AU2018220734A patent/AU2018220734B2/en not_active Expired - Fee Related
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/en active Pending
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
-
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
-
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
-
2025
- 2025-01-07 JP JP2025002125A patent/JP2025061059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3583131A1 (en) | 2019-12-25 |
| JP2020510646A (ja) | 2020-04-09 |
| EP3583131A4 (en) | 2021-03-17 |
| IL268790A (en) | 2019-10-31 |
| US20210130471A1 (en) | 2021-05-06 |
| WO2018152516A1 (en) | 2018-08-23 |
| CN110573530A (zh) | 2019-12-13 |
| JP2023052214A (ja) | 2023-04-11 |
| CA3054078A1 (en) | 2018-08-23 |
| BR112019017277A2 (pt) | 2020-04-14 |
| RU2019129174A (ru) | 2021-03-22 |
| RU2019129174A3 (enExample) | 2021-07-02 |
| KR20190120775A (ko) | 2019-10-24 |
| AU2018220734B2 (en) | 2025-03-06 |
| SG11201907638QA (en) | 2019-09-27 |
| AU2018220734A1 (en) | 2019-09-12 |
| JP2025061059A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47508A (fr) | Protéines de liaison à cd33, nkg2d et cd16 | |
| MA50255A (fr) | Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) | |
| IL268755A (en) | Proteins binding her2, nkg2d and cd16 | |
| IL281305A (en) | Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1 | |
| IL272374A (en) | Proteins binding nkg2d, cd16 and flt3 | |
| IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
| EP3679071A4 (en) | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | |
| IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
| EP3802581A4 (en) | MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THERETO | |
| IL280512A (en) | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use | |
| EP3641762A4 (en) | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION | |
| IL270803A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
| EP3680331A4 (en) | Modified cas9 protein, and use thereof | |
| EP3630181A4 (en) | NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN | |
| IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
| IL268766A (en) | Proteins that bind NKG2D, CD123, and CD16 | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
| MA53284A (fr) | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur | |
| EP3689893A4 (en) | IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE | |
| IL286929A (en) | Trispecific binding proteins, methods, and uses thereof | |
| EP3445394A4 (en) | ALK7-BINDING PROTEINS AND THEIR USE | |
| EP3700571A4 (en) | ALK7-BINDING PROTEINS AND USES THEREOF | |
| IL290715A (en) | nkg2d fusion proteins and their use | |
| GB201704006D0 (en) | Modified globin proteins |